- Organon Announces Pricing of $1.0 Billion Senior Notes Offering
- Organon Announces Proposed $1.0 Billion Senior Notes Offering
- Organon Reports Results for the First Quarter Ended March 31, 2024
- Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
- Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
- Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary
- Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023
More ▼
Key statistics
As of last trade Organon & Co (OGN:NYQ) traded at 20.38, -15.37% below its 52-week high of 24.08, set on Aug 08, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 20.41 |
---|---|
High | 20.75 |
Low | 20.30 |
Bid | 20.37 |
Offer | 20.38 |
Previous close | 20.23 |
Average volume | 2.72m |
---|---|
Shares outstanding | 257.17m |
Free float | 256.77m |
P/E (TTM) | 5.03 |
Market cap | 5.27bn USD |
EPS (TTM) | 4.08 USD |
Annual div (ADY) | 1.12 USD |
---|---|
Annual div yield (ADY) | 5.46% |
Div ex-date | May 10 2024 |
Div pay-date | Jun 13 2024 |
Data delayed at least 15 minutes, as of May 10 2024 18:39 BST.
More ▼